Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acadia Pharmaceutica
(NQ:
ACAD
)
17.00
-0.05 (-0.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Acadia Pharmaceutica
< Previous
1
2
3
4
5
6
Next >
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
January 09, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
January 03, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
December 21, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
November 25, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Acadia Trofinetide Phase III Clinical Top-Line Results Positive
November 16, 2022
Via
AB Newswire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 08, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 02, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
October 31, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
October 27, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
October 20, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
October 13, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
October 04, 2022
From
Acadia Pharmaceuticals
Via
Business Wire
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
September 12, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
September 01, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 08, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
August 04, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
July 25, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
July 18, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
June 17, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Stock Trading Halted Today
June 17, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
May 04, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 03, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
May 02, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
April 21, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
April 18, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
March 22, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
February 16, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
February 14, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
February 11, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
January 10, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.